




# PHARMACEUTICAL 2023

Thorne Healthtech Inc.  
Rank 131 of 446

**THORNE®**





# PHARMACEUTICAL 2023

Thorne Healthtech Inc.  
Rank 131 of 446

**THORNE®**

The relative strengths and weaknesses of Thorne Healthtech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Thorne Healthtech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Thorne Healthtech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	116,621
Cost of Goods Sold	113,797
Intangible Assets	31,871
Liabilities, Current	39,561
Liabilities, Non-Current	28,430
Other Assets	32,135
Other Compr. Net Income	712
Other Expenses	19,133
Other Liabilities	15,160
Other Net Income	2,142
Other Revenues	228,731
Property and Equipment	49,177
Research and Development	7,424
Selling, General and Administrative Expense	75,586

Output Variable	Value in 1000 USD
Assets	229,804
Liabilities	83,152
Expenses	215,940
Revenues	228,731
Stockholders Equity	146,652
Net Income	14,933
Comprehensive Net Income	15,289
Economic Capital Ratio	171%